Clinical Trial

A Study of GC101 TIL in Advanced Solid Tumors (TR)

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with Advanced malignant solid tumors.Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2025-12-22 -> 2027-12-22 2026-08-06
minor Completion pushed: 2026-04-22 -> 2029-04-22 2026-08-06
Trial Details
NCT Number NCT04967833
Lead Sponsor Shanghai Juncell Therapeutics
Collaborators: Shanghai Tong Ren Hospital
Conditions Advanced Solid Tumors
Enrollment 20 participants
Start Date 2021-04-22
Primary Completion 2027-12-22 (estimated)
Study Completion 2029-04-22 (estimated)
Updated on ClinicalTrials.gov 2026-08-05